HK1204622A1 - (2-heteroarylamino)succinic acid derivative (2-) - Google Patents

(2-heteroarylamino)succinic acid derivative (2-)

Info

Publication number
HK1204622A1
HK1204622A1 HK15105297.2A HK15105297A HK1204622A1 HK 1204622 A1 HK1204622 A1 HK 1204622A1 HK 15105297 A HK15105297 A HK 15105297A HK 1204622 A1 HK1204622 A1 HK 1204622A1
Authority
HK
Hong Kong
Prior art keywords
heteroarylamino
succinic acid
acid derivative
derivative
succinic
Prior art date
Application number
HK15105297.2A
Other languages
English (en)
Chinese (zh)
Inventor
Tatsuya Nishi
Naoki Tanaka
Ryoko Kitazawa
Riki Goto
Takashi Ishiyama
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of HK1204622A1 publication Critical patent/HK1204622A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK15105297.2A 2012-03-30 2015-06-03 (2-heteroarylamino)succinic acid derivative (2-) HK1204622A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012079859 2012-03-30
PCT/JP2013/059657 WO2013147216A1 (ja) 2012-03-30 2013-03-29 （２－ヘテロアリールアミノ）コハク酸誘導体

Publications (1)

Publication Number Publication Date
HK1204622A1 true HK1204622A1 (en) 2015-11-27

Family

ID=49260457

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105297.2A HK1204622A1 (en) 2012-03-30 2015-06-03 (2-heteroarylamino)succinic acid derivative (2-)

Country Status (11)

Country Link
US (1) US9206168B2 (ko)
EP (1) EP2832726B1 (ko)
JP (1) JP6100755B2 (ko)
KR (1) KR20140147825A (ko)
CN (1) CN104334528A (ko)
CA (1) CA2869135A1 (ko)
ES (1) ES2649905T3 (ko)
HK (1) HK1204622A1 (ko)
IN (1) IN2014DN08653A (ko)
TW (1) TW201400458A (ko)
WO (1) WO2013147216A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9634549B2 (en) 2013-10-31 2017-04-25 General Electric Company Dual phase magnetic material component and method of forming
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
WO2021003295A1 (en) * 2019-07-02 2021-01-07 Regeneron Pharmaceuticals, Inc. Modulators of hsd17b13 and methods of use thereof
CN111559982B (zh) * 2020-06-09 2023-04-07 天津市医药科学研究所 2-(2-取代-4-羟基嘧啶-5-甲酰胺基)乙酸类化合物及其制备方法与用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509077A (ja) * 1998-02-09 2002-03-26 ユニヴァースティ オブ サザーン カリフォルニア 赤血球形成促進方法
CN104876904A (zh) * 2002-03-08 2015-09-02 卫材R&D管理株式会社 用作医药品的大环化合物
EP1893186A2 (en) * 2005-06-06 2008-03-05 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
HUE041300T2 (hu) * 2006-06-26 2019-05-28 Akebia Therapeutics Inc Prolilhidroxiláz inhibitorok és alkalmazási eljárások
JP5557832B2 (ja) 2008-03-18 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 置換４−ヒドロキシピリジン−５−カルボキサミド
CN101980787B (zh) * 2008-04-01 2012-11-21 伟尔矿物澳大利亚私人有限公司 用于破碎机的提升杆组件及安装方法
CA2722028C (en) * 2008-04-22 2013-09-24 Daiichi Sankyo Company, Limited 5-hydroxypyrimidine-4-carboxamide compound
CN102802629A (zh) 2009-06-30 2012-11-28 默沙东公司 取代的4-羟基嘧啶-5-甲酰胺
US8372857B2 (en) 2009-06-30 2013-02-12 Merck Sharp & Dohme Corp. Substituted 4-hydroxypyrimidine-5-carboxamides
EP2492266B1 (en) 2009-10-21 2015-08-26 Daiichi Sankyo Company, Limited 5-hydroxypyrimidine-4-carboxamide derivative
JP2011105708A (ja) * 2009-10-21 2011-06-02 Daiichi Sankyo Co Ltd ５−ヒドロキシピリミジン−４−カルボキサミド化合物を含有する医薬組成物
JP2011088840A (ja) * 2009-10-21 2011-05-06 Daiichi Sankyo Co Ltd ５−ヒドロキシピリミジン−４−カルボキサミド化合物を含有する医薬組成物
TWI412114B (zh) * 2009-12-31 2013-10-11 Advanced Semiconductor Eng 半導體封裝結構及其製造方法
TW201141839A (en) * 2010-04-19 2011-12-01 Daiichi Sankyo Co Ltd Substituted 5-hydroxypyrimidine-4-carboxamide compounds

Also Published As

Publication number Publication date
US9206168B2 (en) 2015-12-08
US20150011574A1 (en) 2015-01-08
JPWO2013147216A1 (ja) 2015-12-14
WO2013147216A1 (ja) 2013-10-03
TW201400458A (zh) 2014-01-01
KR20140147825A (ko) 2014-12-30
CA2869135A1 (en) 2013-10-03
JP6100755B2 (ja) 2017-03-22
ES2649905T3 (es) 2018-01-16
IN2014DN08653A (ko) 2015-05-22
EP2832726A4 (en) 2015-12-02
EP2832726B1 (en) 2017-09-06
EP2832726A1 (en) 2015-02-04
CN104334528A (zh) 2015-02-04

Similar Documents

Publication Publication Date Title
HK1211569A1 (en) Amino acid derivatives
AP4063A (en) Dimethyl-benzoic acid compounds
HK1207375A1 (en) Piperidinylpyrazolopyridine derivative
HK1207363A1 (en) Novel indanesulfamide derivative
GB201214842D0 (en) Content tracker
HK1205692A1 (en) Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance ---
HK1204622A1 (en) (2-heteroarylamino)succinic acid derivative (2-)
EP2872301A4 (en) STRUCTURE FOR ROBOTS
HK1200824A1 (en) Substituted phenylazole derivative
PT2873660T (pt) Derivado de indolecarboxamida
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
EP2842958A4 (en) NAPHTHOBISTHIADIAZOLDERIVAT
HUE040533T2 (hu) Terményemelõ
HK1204621A1 (en) 4-alkanoylamino-3-pyrazolone derivative 4--3-
HK1212895A1 (zh) 用於免疫調節的沙奎那韋-
GB201220556D0 (en) Sustained-release formulation
GB201214413D0 (en) Festivalstand (festistand)
GB201223266D0 (en) Glycopolymers
GB201213825D0 (en) Damper-device for bouncing-device
TWM433497U (en) Structure for jacklight
GB201200945D0 (en) Festival stand (festistand)
GB201206547D0 (en) Sustained-release formulation
GB201203779D0 (en) (LASERComfortSET)